None that I've seen published...but given the comparison i made earlier, I think it would be a stretch to think this drug is going to have much success in patients resistant to ponatinib.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.